Clinical Trials Browser

Phase 1/2 × Carcinoma, Renal Cell × Standard of Care × Clear all

NCT07053462 2025-07-08

CRISPR-Edited HLA Donor Kidney Transplant to Reduce Rejection Risk

Phase 1/2 Recruiting

Carcinoma, Renal Cell, Kidney Failure, Chronic, Renal Insufficiency